![Vrije Universiteit Brussel / Immune system / Immunotherapy / Merck & Co. / Single-domain antibody / Serono / Pharmaceutical industry / Cancer immunotherapy / Medicine / Immunology / Ablynx Vrije Universiteit Brussel / Immune system / Immunotherapy / Merck & Co. / Single-domain antibody / Serono / Pharmaceutical industry / Cancer immunotherapy / Medicine / Immunology / Ablynx](https://www.pdfsearch.io/img/0fcf055271e7661d64f843fb054084c4.jpg)
| Document Date: 2014-02-02 12:55:18 Open Document File Size: 377,00 KBShare Result on Facebook
City GHENT / Brussels / / Company Merck & Co. / Eddingpharm / Novartis / AbbVie / Ablynx / Merck Research Laboratories / Boehringer Ingelheim / Merck Serono / / Country Belgium / United States / Canada / / Currency EUR / / / Event Business Partnership / / IndustryTerm media relations / biopharmaceutical / treatment of a wide range of cancer / manufacturing / pharmaceutical / / MedicalCondition cancer / serious human diseases / pulmonary disease / inflammation / tumours / / MedicalTreatment immunotherapies / / Person Edwin Moses / Roger M. Perlmutter / Lindsey Neville / / / Position CEO / President / Director Investor Relations / / Product Nanobody platform / Nanobody / / Technology neuroscience / immunotherapeutics / Nanobody technology / / URL www.ablynx.com / /
SocialTag |